NCT02388009View on ClinicalTrials.gov

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Shigellosis
Interventions
BIOLOGICAL

Flexyn2a

Intramuscular doses of 0.5 mL

BIOLOGICAL

Placebo

Intramuscular doses of 0.5 mL

BIOLOGICAL

Flexyn2a plus adjuvant

Intramuscular doses of 0.5 mL

Trial Locations (1)

20910

WRAIR Clinical Trial Center (CTC), Silver Spring

Sponsors
All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

Naval Medical Research Center

FED

lead

LimmaTech Biologics AG

INDUSTRY